Development of pemphigus vulgaris during treatment with dipeptidyl peptidase‐4 inhibitors: a case report

Abstract

Pemphigus vulgaris (PV), a rare autoimmune disease, affects the skin and mucous membranes via autoantibodies to desmoglein 3 (Dsg3) and/or desmoglein 1 (Dsg1). 1 Although dipeptidyl peptidase-4 inhibi-

Dipeptidyl peptidase‐4 inhibitor‐related pemphigus herpetiformis with antibodies against desmocollin 3

“…To our knowledge, there have been three cases of pemphigus related to DPP4i and six cases of pemphigus with antibodies exclusively targeting Dsc3 (Table 1). [1][2][3][4] Our case improved with a milder treatment compared to pemphigus vulgaris (PV). Dsc3 antibodypositive PH without mucosal rash is also recognized, possibly because DSC plays a less critical role in cell-cell adhesion than DSG, or due to compensation of DSC dysfunction by other DSC molecules.…”